Avalanche Biotechnologies (AAVL) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Avalanche Biotechnologies (AAVL) PT Lowered to $25 at Piper Jaffray on Q2 Results and Wet-AMD Update
August 14, 2015 6:50 AM EDTPiper Jaffray analyst Joshua Schimmer cut his price target on Avalanche Biotechnologies (NASDAQ: AAVL) to $25.00 (from $30.00) following Q2 results and the Wet-AMD updated but maintained an Overweight rating.
Schimmer commented, "After the close, AAVL reported 2Q15 earnings and, not surprisingly, disclosed... More



